107 matching studies

Sponsor Condition of Interest
Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects...
Pluristem Ltd. Critical Limb Ischemia (CLI)
This will be a randomized, placebo-controlled, parallel group, multicenter, Phase III study.The study aims to evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects with Critical Limb Ischemia (CLI) with Minor Tissue... expand

This will be a randomized, placebo-controlled, parallel group, multicenter, Phase III study.The study aims to evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects with Critical Limb Ischemia (CLI) with Minor Tissue Loss (Rutherford Category 5) who are Unsuitable for Revascularization.

Type: Interventional

Start Date: May 2017

open study

Antioxidant Use in Diabetes to Reduce Oxidative Stress
University of Maryland, College Park Ameliorating Oxidative Stress in Type 1 Diabetes
Dietary supplementation with antioxidant vitamins, such as Vitamin C and Vitamin E, reduces malformation rates in embryos of diabetic animals. However, human trials exploring the benefits of these antioxidant vitamins have produced unsatisfactory results in trials designed to... expand

Dietary supplementation with antioxidant vitamins, such as Vitamin C and Vitamin E, reduces malformation rates in embryos of diabetic animals. However, human trials exploring the benefits of these antioxidant vitamins have produced unsatisfactory results in trials designed to alleviating diabetic retinopathy, cardiovascular disease, and preeclampsia in pregnancies. The investigators hypothesize that more potent, and better-targeted antioxidants, such as N-acetylcysteine (NAC) and Polyunsaturated Fatty Acids(PUFA), will be successful in preventing birth defects in the offspring of women with diabetes.

Type: Interventional

Start Date: Nov 2018

open study

Ceramide NanoLiposome in Patients With Advanced Solid Tumors
Keystone Nano, Inc Cancer Carcinoma Solid Tumors Tumor
This study is a dose escalation study of Ceramide NanoLiposome in patients with advanced solid tumors. expand

This study is a dose escalation study of Ceramide NanoLiposome in patients with advanced solid tumors.

Type: Interventional

Start Date: Mar 2017

open study

Prophylactic Topical Epinephrine to Reduce Bleeding in Transbronchial Lung Biopsies
University of Maryland, College Park Lung Transplant; Complications, Mechanical Lung Transplant; Complications Bleeding Hemoptysis
Bleeding poses potential for significant complication after transbronchial lung biopsies. The investigators hypothesize that prophylactic intrabronchial instillation of topical epinephrine will reduce the likelihood of bleeding. The investigators plan a double-blind, placebo... expand

Bleeding poses potential for significant complication after transbronchial lung biopsies. The investigators hypothesize that prophylactic intrabronchial instillation of topical epinephrine will reduce the likelihood of bleeding. The investigators plan a double-blind, placebo controlled trial to evaluate this hypothesis.

Type: Interventional

Start Date: Jul 2017

open study

Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
Adaptimmune Solid and Hematological Malignancies
This screening study is intended for men and women at least 18 years of age who have advanced solid or hematologic malignancy. The study will assess a subject's human leukocyte antigen (HLA) subtype and tumor antigen expression profile. Based on the results, it will be determined... expand

This screening study is intended for men and women at least 18 years of age who have advanced solid or hematologic malignancy. The study will assess a subject's human leukocyte antigen (HLA) subtype and tumor antigen expression profile. Based on the results, it will be determined if a subject is eligible to be considered for Adaptimmune sponsored clinical trials testing the safety and efficacy of genetically changed T cells targeting specific tumor antigens. No treatment intervention will occur as part of this screening study. Upon enrollment, subjects will be required to provide a blood sample for HLA subtype analysis. If the results of the analysis match the HLA-A subtypes noted in the inclusion criteria and do not express the HLA subtypes that are exclusionary for the available interventional clinical trial(s), then the subject will be required to provide either an archival tumor specimen or fresh tumor tissue biopsy. The tumor specimen will be screened at a central laboratory for the expression (protein or gene) of multiple antigens which may include, but are not limited to NY-ESO-1 and/or LAGE-1a and MAGE A10. Based upon the results of these diagnostic analyses, if eligible, subjects will be referred to an appropriate available interventional clinical trial(s) at the discretion of the Investigator. Following screening, tumor samples will be retained by Adaptimmune for the purpose of developing and validating in vitro diagnostic (IVD) assay(s) for antigen expression profiling which is required for regulatory approval of a new therapeutic product indication.

Type: Observational

Start Date: Dec 2015

open study

Intraoperative Cryoanalgesia for Extended Pain Management Following Thoracotomy
University of Maryland, College Park Chronic Post-thoracotomy Pain Acute Post-thoracotomy Pain Post-thoracotomy Pain Syndrome
The ICE Study study will compare standard therapy (thoracic epidural) versus a novel approach (Cryoanalgesia combined with thoracic epidural) in subjects undergoing unilateral thoracotomy. expand

The ICE Study study will compare standard therapy (thoracic epidural) versus a novel approach (Cryoanalgesia combined with thoracic epidural) in subjects undergoing unilateral thoracotomy.

Type: Interventional

Start Date: Sep 2018

open study

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of...
Onconova Therapeutics, Inc. Myelodysplastic Syndrome MDS Refractory Anemia With Excess Blasts RAEB
The study's primary objective [in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)], is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup... expand

The study's primary objective [in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)], is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk.

Type: Interventional

Start Date: Oct 2015

open study